SEC Filing Summary: Form 13F Information Table
Business Context and Reporting Period
Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Type: Form 13F Information Table
Reporting Period: As of September 30, 2024
This filing discloses the equity securities held by Takeda Pharmaceutical Co Ltd as of the end of the third quarter of 2024. The document lists specific holdings in various biotechnology and healthcare-related companies, detailing share counts, market values, and voting authority.
Key Financial Metrics and Holdings
The filing does not report Takeda's consolidated revenue, profit, cash flow, or debt. Instead, it provides a snapshot of specific equity investments. Key metrics from the table include:
- Total Disclosed Positions: 12 distinct line items across 10 issuers.
- Largest Position by Value: HilleVax, Inc. (11,834,640 shares, valued at $6,724,000).
- Largest Position by Share Count: HilleVax, Inc. (11,834,640 shares).
- Voting Authority: Most positions are held with "Discretionary" (DFND) authority, with some held "Solely" (SOLE).
| Issuer | Shares Held | Value (USD) | Voting Authority |
|---|---|---|---|
| HilleVax, Inc. | 11,834,640 | $6,724,000 | Discretionary |
| Ovid Therapeutics Inc. | 6,785,000 | $5,750,000 | Discretionary |
| Ovid Therapeutics Inc. | 2,102,755 | $1,781,996 | Sole |
| Equillium, Inc. | 1,514,731 | $1,824,977 | Discretionary |
| Wave Life Sciences Ltd. | 8,994,514 | $1,096,892 | Sole |
| Xilio Therapeutics, Inc. | 1,162,395 | $1,475,121 | Discretionary |
Note: The table above lists selected major holdings. Full details for all 12 line items are available in the source text.
Material Changes and Comparisons
The filing text does not provide data for the prior comparable period (June 30, 2024). Therefore, no material changes in holdings, values, or voting authority can be calculated or summarized from this document alone.
Guidance, Outlook, and Risks
Management Commentary: None provided in this filing.
Guidance/Outlook: None provided. Form 13F is a regulatory disclosure of holdings and does not contain forward-looking statements.
Risks and Contingencies: The filing includes a standard disclaimer that the SEC has not reviewed the information for accuracy or completeness. No specific operational or financial risks regarding the underlying portfolio companies are detailed in this text.
Investor Verification Checklist
- Verify the total aggregate value of Takeda's disclosed equity portfolio against the company's broader investment strategy.
- Confirm the voting authority status (Sole vs. Discretionary) for significant positions like Ovid Therapeutics and Wave Life Sciences to understand control implications.
- Compare these holdings against the previous quarter's 13F filing to identify new entries or exits (data not present in this text).
- Review the specific CUSIPs provided to ensure accurate identification of the securities, particularly for issuers with multiple classes or recent corporate actions.